ASCO GU 2018: Treatment Facility Volume and Survival in Patients with metastatic Renal Cell Carcinoma
San Francisco, CA (UroToday.com) Prognosis of metastatic renal cell carcinoma (mRCC) has significantly improved in the targeted therapy era. Novel therapies continue to be developed for mRCC, making the management much more nuanced.
ASCO GU 2018: Carcinomas of the Renal Medulla: A Comprehensive Genomic Profiling Study
San Francisco, CA (UroToday.com) Collecting duct carcinoma (CDC) and renal medullary carcinoma (RMC) represent rare renal tumors that arise in the renal medulla, resistant to therapy, and progress rapidly.
ASCO GU 2018: Association of Dividing Pathologically Upstaged T3a Renal Cell Carcinoma with Improved Alignment of Outcomes: A Call for TMN Revision
San Francisco, CA (UroToday.com) Incidental pathological upstaging to pT3a disease can occur after surgical treatment of clinical T1 and T2 Renal Cell Carcinoma (RCC), and upstaged pT3a disease is associated with worsened outcomes. Oncologic and survival outcomes within the pT3a category are heterogeneous. The authors investigated recurrence and survival outcomes in pT3a disease, and aimed to better categorize this cohort for improvement on current TMN staging.
ASCO GU 2018: A Phase III Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy
San Francisco, CA (UroToday.com) The anti-PD-1 antibody nivolumab (nivo) improves overall survival (OS) in metastatic treatment refractory RCC and is generally tolerable. In 2017, there is no standard adjuvant therapy proven to increase OS over surgery alone in non-metastatic (M0) disease. Mouse solid tumor models have revealed an OS benefit with a short course of neoadjuvant PD-1 blockade compared to adjuvant therapy.
ASCO GU 2018: Treatment trends of localized renal cell carcinoma by hospital type: A NCDB analysis
San Francisco, CA (UroToday.com) Accounting for operative, oncologic and comorbid risks guide treatment recommendations for localized kidney cancers. The authors hypothesized that individualized surgical decision making may also be influenced by surgical center and volume.
ASCO GU 2018: Effects of Patient Gender on Urologist Decision-Making Regarding Treatment of the Localized Renal Mass Introduction and Objective
San Francisco, CA (UroToday.com) Gender disparity in the proportion of patients receiving nephron sparing strategies (NSS) for the treatment of localized renal masses has been demonstrated in large population series as well as in single centers of excellence. However, the reasons for the gender discrepancy remains elusive. The authors aimed to assess urologist treatment patterns for localized renal masses in both genders to gauge the existence of provider-based gender biases. It was hypothesized that female patients may be recommended more aggressive treatment due to provider biases related to patient gender.
ASCO GU 2018: Systemic Immune Inflammation Index and Treatment Response in Patients with Metastatic Renal Cell Cancer
San Francisco, CA (UroToday.com) Biomarkers to predict response are highly sought after, as they can help reduce overtreatment and help prevent delay to appropriate treatment. Inflammatory markers have been assessed in multiple malignancies. In this smaller institutional series, the authors investigate the prognostic value of the pretreatment inflammatory characteristics on treatment response and survival in patients with metastatic renal cell carcinoma (mRCC). It was a study of 149 patients, and was completed as a retrospective study.